What the PEARL Trial Actually Showed About Rapamycin

The one-sentence version

PEARL was the largest decentralized randomized trial of low-dose rapamycin in healthy, normally-aging adults to date — and it missed its primary endpoint: rapamycin did not significantly reduce visceral fat¹. The signals people quote from PEARL (lean mass, pain, well-being) are all secondary or subgroup findings, several of them confined to women at the higher dose. That distinction — primary-endpoint failure versus cherry-picked secondary signals — is the whole story, and it is exactly the distinction the marketing tends to blur. For where rapamycin sits in the wider toolkit, see our pillar on longevity medicine: what's proven vs hyped, and for the full drug profile, rapamycin for longevity: hype vs evidence.

What PEARL was

PEARL ("Participatory Evaluation of Aging with Rapamycin for Longevity") was a 48-week, double-blinded, placebo-controlled, decentralized RCT (NCT04488601) run by the telehealth company AgelessRx. Healthy adults were randomized to weekly placebo, 5 mg, or 10 mg of compounded oral rapamycin, with outcomes assessed by DXA scan, blood biomarkers, and validated questionnaires¹.

Two design features are worth flagging up front, because they shape how much weight the results can bear:

• •It was sponsor-run. Every listed author is an employee and shareholder of AgelessRx, a company that sells rapamycin prescriptions. That doesn't make the data wrong, but it is a conflict of interest the paper itself discloses, and it warrants the same skepticism you'd apply to any industry-funded trial of its own product¹.
• •It was decentralized and self-report-heavy. Recruiting and measuring participants remotely is what made the trial feasible at scale, but it also means several headline outcomes (pain, emotional well-being, general health) came from surveys rather than hard clinical endpoints.

The primary endpoint: a miss

PEARL pre-specified visceral adiposity (visceral fat, measured by DXA) as its single primary outcome. This is the cleanest fact in the entire readout, and it is the one most often skipped: visceral fat did not change significantly. The effect size was essentially zero (partial η² = 0.001, p = 0.942) — not a near-miss, not a trend, but a flat result¹.

In a trial, the primary endpoint is the question the study was actually powered and designed to answer. When it comes back null, the honest summary is "the trial did not show its intended effect." Everything else — every secondary or subgroup signal — is hypothesis-generating, not confirmatory. PEARL's authors are reasonably candid about this in their conclusions, framing the study as establishing relative safety and pointing to "future work" to "more comprehensively establish efficacy"¹. That is the language of a trial that did not establish efficacy.

The secondary and subgroup signals

So what did reach significance? A handful of secondary outcomes, and the framing matters for each one:

• •Lean tissue mass improved — but only for women on 10 mg (partial η² = 0.202, p = 0.013). This was not an effect across the whole randomized population; it was a subgroup finding in one sex at one dose¹.
• •Self-reported pain improved — again only for women on 10 mg (partial η² = 0.168, p = 0.015), measured by questionnaire¹.
• •Self-reported emotional well-being and general health improved for the 5 mg group (p = 0.023 and p = 0.004), also by questionnaire¹.
• •Blood biomarkers stayed within normal ranges, and adverse and serious adverse events were similar across all arms — the safety signal that was the study's stated reason for being¹.

Here is the problem with leaning on these. A trial that measures many outcomes across multiple dose arms and subgroups will, by chance alone, turn up some "significant" results even if the drug does nothing. The fact that the lean-mass and pain wins are confined to a single sex at a single dose, and that two more depend on self-report, is exactly the pattern that should lower — not raise — your confidence. None of these were the pre-specified primary endpoint, none were corrected for the number of comparisons in the headline framing, and the strongest of them sit in a women-at-10 mg subgroup that the trial was not designed or powered to test as a primary question.

That is not a knock on the investigators for reporting them — secondary signals are worth reporting. It is a knock on anyone who repackages "women on 10 mg had more lean mass" as "PEARL proves rapamycin works."

What PEARL does and doesn't support

What it reasonably supports: intermittent low-dose rapamycin (5–10 mg weekly) over roughly a year was relatively safe in a healthy adult cohort, with adverse events comparable to placebo and blood biomarkers staying in range¹. That is a genuine, useful contribution — short-term tolerability data in healthy people is scarce, and this adds to it alongside an earlier randomized feasibility trial in older adults that likewise found short-course rapamycin tolerable².

What it does not support: that rapamycin reduces visceral fat (the thing it was designed to test — it didn't), or that it has been shown to slow aging, extend healthspan, or improve any aging biomarker in a confirmatory way. An authoritative review of mTOR inhibitors in aging states the ceiling plainly: no rapalog has been shown to extend human lifespan or healthspan, and the human evidence base remains early³. PEARL doesn't change that sentence. It is consistent with it.

This is why, on our evidence hierarchy, rapamycin still grades as "best-in-class animal lifespan data, absent human-longevity proof" even after PEARL. A null primary endpoint in a sponsor-run, self-report-heavy trial is not the level-1 human outcome data the longevity field keeps promising.

How this fits the rest of the rapamycin story

PEARL is the most-cited human rapamycin-for-longevity trial precisely because there is so little else. The drug's reputation rests almost entirely on mouse data — the rigorous NIA Interventions Testing Program found rapamycin extends lifespan in mice even when started late in life, the most reproducible pharmacologic lifespan result in the field³. The most encouraging functional human signal comes not from rapamycin but from a related rapalog: low-dose everolimus improved the immune response to vaccination in older adults⁴, and a follow-up reported a TORC1 inhibitor reduced respiratory infections in the elderly⁵ — though that program later missed its primary endpoint in a larger confirmatory trial. None of that is a longevity outcome.

And the risks the safety data must be weighed against are real: rapamycin is a prescription immunosuppressant with documented effects on glucose handling and pancreatic β-cells⁶, and reviews are explicit that the optimal dose and long-term safety for healthy people are still unsettled⁷. PEARL's reassuring one-year safety picture is welcome, but one year in a self-selected healthy cohort is not the same as established long-term safety. We cover both drugs' human-trial gap together in rapamycin & metformin for longevity: the evidence.

If a clinic cites PEARL at you

Some longevity clinics — including the one that ran the trial — point to PEARL as evidence rapamycin "works." Use the primary-endpoint test. A trustworthy provider will tell you, in plain language, that PEARL's main outcome (visceral fat) was null, that the positive findings were secondary or subgroup signals (several in women at 10 mg, several self-reported), and that the trial's real contribution was short-term safety, not proof of anti-aging benefit. A provider that presents PEARL as a green light has already failed our trust test. For how we vet providers on exactly this kind of honesty, see are longevity clinics worth it? and our independently graded longevity clinic rankings.

Bottom line

PEARL deserves credit for being a real, randomized, placebo-controlled trial in a field full of anecdote — and for showing that low-dose intermittent rapamycin is relatively safe over a year in healthy adults. But it missed the endpoint it was built to test: visceral fat didn't budge. The signals worth talking about are secondary, mostly confined to women on the higher dose, and partly self-reported — interesting leads, not proof. The honest reading is that PEARL tempers the rapamycin-longevity hype rather than confirming it. The science is genuinely worth continuing; it is also genuinely unfinished.